BioCentury
ARTICLE | Company News

EpiCept, Myrexis deal

September 10, 2012 7:00 AM UTC

EpiCept said that Myrexis terminated a 2003 deal and returned rights to cancer compound Azixa verubulin to EpiCept. Myrexis discontinued development of Azixa last year. The small molecule microtubule destabilizing apoptosis-inducer was in Phase IIb testing for glioblastoma multiforme (GBM). EpiCept said the compound is available for partnering. The companies did not disclose details. ...